{"id":"trastuzumab-monotherapy","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"20-30%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Musculoskeletal pain"}]},"_chembl":{"chemblId":"CHEMBL1201585","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Trastuzumab is a monoclonal antibody that selectively binds to the extracellular domain of the human epidermal growth factor receptor 2 (HER2/neu). This binding leads to the internalization and degradation of the receptor, which in turn inhibits the proliferation of cancer cells that overexpress HER2/neu. Additionally, trastuzumab can induce antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), further contributing to its anti-tumor effects.","oneSentence":"Trastuzumab targets and binds to the HER2/neu receptor on cancer cells, triggering an immune response and inhibiting cell growth.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:39:57.181Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjuvant treatment of HER2-positive breast cancer"},{"name":"Treatment of HER2-positive metastatic breast cancer"}]},"trialDetails":[{"nctId":"NCT07060807","phase":"PHASE3","title":"A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-21","conditions":"Breast Neoplasms","enrollment":1000},{"nctId":"NCT06625775","phase":"PHASE1","title":"Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors","status":"RECRUITING","sponsor":"TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)","startDate":"2024-10-29","conditions":"Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer","enrollment":392},{"nctId":"NCT04639219","phase":"PHASE2","title":"A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-12-30","conditions":"Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast","enrollment":102},{"nctId":"NCT04802759","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-06-22","conditions":"Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer","enrollment":316},{"nctId":"NCT01042379","phase":"PHASE2","title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2010-03-01","conditions":"Breast Neoplasms, Breast Cancer, Breast Tumors","enrollment":5000},{"nctId":"NCT05417594","phase":"PHASE1, PHASE2","title":"Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2022-06-24","conditions":"Advanced Solid Malignancies","enrollment":695},{"nctId":"NCT07069712","phase":"PHASE2","title":"A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-07-17","conditions":"Gastroesophageal Adenocarcinoma","enrollment":100},{"nctId":"NCT06819007","phase":"PHASE3","title":"Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2025-03-19","conditions":"Ovarian Cancer","enrollment":582},{"nctId":"NCT07124000","phase":"","title":"DESTINY-PANTUMOUR04","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-09-18","conditions":"Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer","enrollment":100},{"nctId":"NCT05081609","phase":"PHASE1, PHASE2","title":"A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ascendis Pharma Oncology Division A/S","startDate":"2022-01-11","conditions":"Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor","enrollment":320},{"nctId":"NCT05113251","phase":"PHASE3","title":"Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-10-25","conditions":"Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer","enrollment":927},{"nctId":"NCT04379596","phase":"PHASE2","title":"Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2020-06-03","conditions":"Gastric Cancer","enrollment":450},{"nctId":"NCT04644068","phase":"PHASE1, PHASE2","title":"Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-11-12","conditions":"Ovarian Cancer, Breast Cancer, Pancreatic Cancer","enrollment":702},{"nctId":"NCT06595563","phase":"PHASE2","title":"HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"Jules Bordet Institute","startDate":"2026-02","conditions":"HER2-positive Metastatic Breast Cancer, HER2-positive Advanced Breast Cancer","enrollment":87},{"nctId":"NCT07417241","phase":"PHASE2","title":"SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2026-03-31","conditions":"Breast Cancer, HER2-positive Breast Cancer","enrollment":100},{"nctId":"NCT05993234","phase":"","title":"A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)","status":"RECRUITING","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2023-12-05","conditions":"HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma","enrollment":257},{"nctId":"NCT07394218","phase":"PHASE2","title":"ctDNA-guided Treatment Decision-making","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-12-24","conditions":"Metastatic Breast Cancer ( HER2 Negative), ctDNA","enrollment":122},{"nctId":"NCT07389876","phase":"","title":"Albumin-bound Paclitaxel-based Second-line Treatment Regimens for Locally Advanced or Metastatic G/GEJ Adenocarcinoma","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-09-01","conditions":"Gastric Cancer, Second-line Treatment","enrollment":250},{"nctId":"NCT07037199","phase":"PHASE2","title":"Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-08-18","conditions":"Advanced Breast Cancer","enrollment":45},{"nctId":"NCT03095352","phase":"PHASE2","title":"Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease","status":"COMPLETED","sponsor":"Laura Huppert, MD, BA","startDate":"2017-09-02","conditions":"Breast Cancer, Chest Wall Disease","enrollment":76},{"nctId":"NCT07216105","phase":"PHASE1","title":"FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Fate Therapeutics","startDate":"2025-11-04","conditions":"Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer","enrollment":113},{"nctId":"NCT04538742","phase":"PHASE1, PHASE2","title":"A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-12-28","conditions":"Metastatic Breast Cancer","enrollment":245},{"nctId":"NCT07257380","phase":"PHASE2","title":"Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment: An Adaptive Trial (MRD-ATLAS)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-12-30","conditions":"Gastric / Gastroesophageal Junction Adenocarcinoma","enrollment":90},{"nctId":"NCT05530057","phase":"PHASE2","title":"Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2020-02-18","conditions":"Advanced Breast Cancer","enrollment":180},{"nctId":"NCT03498521","phase":"PHASE2","title":"A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-07-10","conditions":"Cancer of Unknown Primary Site","enrollment":529},{"nctId":"NCT06271837","phase":"PHASE2","title":"A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-02-18","conditions":"Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)","enrollment":175},{"nctId":"NCT06145308","phase":"PHASE2","title":"Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing","status":"RECRUITING","sponsor":"Peking Union Medical College","startDate":"2023-08-15","conditions":"Salivary Gland Carcinoma, Precision Therapy","enrollment":39},{"nctId":"NCT06239467","phase":"PHASE1","title":"First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer","status":"RECRUITING","sponsor":"OnKure, Inc.","startDate":"2024-02-26","conditions":"Advanced Cancer, Breast Cancer, Advanced Solid Tumors","enrollment":200},{"nctId":"NCT07086768","phase":"PHASE1","title":"Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced or Metastatic Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Lei Zheng","startDate":"2026-01-01","conditions":"Solid Tumor, Advanced Solid Tumor, Metastatic Solid Tumor","enrollment":57},{"nctId":"NCT07151586","phase":"PHASE2","title":"Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"UNICANCER","startDate":"2025-10","conditions":"Triple Negative Breast Neoplasms, Neoplasm Metastasis, HER 2 Low-expressing Breast Cancer","enrollment":260},{"nctId":"NCT06490536","phase":"PHASE3","title":"The Sagittarius Trial","status":"RECRUITING","sponsor":"IFOM ETS - The AIRC Institute of Molecular Oncology","startDate":"2024-10-22","conditions":"Colon Cancer Stage II, Colon Cancer Stage III","enrollment":700},{"nctId":"NCT07134153","phase":"PHASE1, PHASE2","title":"Phase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal/Brain Metastases","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-04-18","conditions":"Breast Cancer","enrollment":139},{"nctId":"NCT07078305","phase":"PHASE2","title":"Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellular Carcinoma After First-line Treatment","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-08","conditions":"Hepatocellular Carcinoma","enrollment":134},{"nctId":"NCT05650879","phase":"PHASE1","title":"ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Enliven Therapeutics","startDate":"2023-03-20","conditions":"HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation","enrollment":198},{"nctId":"NCT03094052","phase":"PHASE2","title":"Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2018-10-09","conditions":"HER2-positive Breast Cancer, Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7","enrollment":11},{"nctId":"NCT04188548","phase":"PHASE1","title":"A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2019-12-10","conditions":"Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":500},{"nctId":"NCT02314481","phase":"PHASE2","title":"Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity","status":"ACTIVE_NOT_RECRUITING","sponsor":"University College, London","startDate":"2017-05-12","conditions":"Non-small Cell Lung Cancer","enrollment":50},{"nctId":"NCT06589830","phase":"PHASE2","title":"TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Teligene Ltd.","startDate":"2025-07","conditions":"Colorectal Cancer Metastatic, Advanced Colorectal Cancer","enrollment":80},{"nctId":"NCT01828021","phase":"PHASE2","title":"Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer","status":"COMPLETED","sponsor":"MacroGenics","startDate":"2013-03","conditions":"Breast Cancer","enrollment":25},{"nctId":"NCT03043313","phase":"PHASE2","title":"Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer","status":"COMPLETED","sponsor":"Seagen Inc.","startDate":"2017-06-23","conditions":"Metastatic Colorectal Adenocarcinoma","enrollment":117},{"nctId":"NCT04989816","phase":"PHASE2","title":"Study of T-DXd Monotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior Regimens","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-08-20","conditions":"Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma","enrollment":95},{"nctId":"NCT05034887","phase":"PHASE2","title":"Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients with HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"National Cancer Center Hospital East","startDate":"2022-01-31","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":64},{"nctId":"NCT06525298","phase":"PHASE1, PHASE2","title":"EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors","status":"RECRUITING","sponsor":"Eisbach Bio GmbH","startDate":"2024-09-09","conditions":"Advanced Solid Tumor, Homologous Recombination Deficiency, HRR Deficiency","enrollment":144},{"nctId":"NCT04092673","phase":"PHASE1, PHASE2","title":"Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies","status":"RECRUITING","sponsor":"Effector Therapeutics","startDate":"2019-10-25","conditions":"Solid Tumor, Adult","enrollment":30},{"nctId":"NCT01953926","phase":"PHASE2","title":"Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations","status":"TERMINATED","sponsor":"Puma Biotechnology, Inc.","startDate":"2013-09-30","conditions":"Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations","enrollment":582},{"nctId":"NCT05238831","phase":"EARLY_PHASE1","title":"SMMART Adaptive Clinical Treatment (ACT) Trial","status":"WITHDRAWN","sponsor":"OHSU Knight Cancer Institute","startDate":"2023-01-30","conditions":"Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma","enrollment":""},{"nctId":"NCT04965519","phase":"PHASE2","title":"A Study of RC48-ADC for the Treatment of HER2-expressing Gynecological Malignancies","status":"UNKNOWN","sponsor":"RemeGen Co., Ltd.","startDate":"2021-12-21","conditions":"Gynecological Malignancy","enrollment":120},{"nctId":"NCT02297698","phase":"PHASE2","title":"Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients","status":"COMPLETED","sponsor":"Cancer Insight, LLC","startDate":"2014-10","conditions":"Breast Cancer","enrollment":100},{"nctId":"NCT06098898","phase":"EARLY_PHASE1","title":"Safety and Efficacy of NK510 to Treat Gastric Cancer","status":"UNKNOWN","sponsor":"Base Therapeutics (Shanghai) Co., Ltd.","startDate":"2023-11-01","conditions":"Gastric Cancer","enrollment":9},{"nctId":"NCT05395052","phase":"PHASE1","title":"FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors","status":"TERMINATED","sponsor":"Fate Therapeutics","startDate":"2022-05-31","conditions":"Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer","enrollment":5},{"nctId":"NCT01969643","phase":"PHASE1","title":"A Safety Study of SGN-LIV1A in Breast Cancer Patients","status":"COMPLETED","sponsor":"Seagen Inc.","startDate":"2013-10-22","conditions":"HER2 Positive Breast Neoplasms, Hormone Receptor Positive Breast Neoplasms, Triple Negative Breast Neoplasms","enrollment":290},{"nctId":"NCT05725200","phase":"PHASE2","title":"Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2022-09-27","conditions":"Metastatic Colorectal Cancer","enrollment":40},{"nctId":"NCT02627274","phase":"PHASE1","title":"A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-12-07","conditions":"Solid Tumor, Breast Cancer, Cancer of Head and Neck","enrollment":134},{"nctId":"NCT05346861","phase":"PHASE3","title":"Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2021-09-15","conditions":"HER2-positive Breast Cancer, Metastatic Breast Cancer","enrollment":240},{"nctId":"NCT01587040","phase":"PHASE1, PHASE2","title":"Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-07-20","conditions":"Neoplasm Malignant","enrollment":61},{"nctId":"NCT05292742","phase":"PHASE2","title":"Compare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast Cancer","status":"RECRUITING","sponsor":"Fujian Medical University Union Hospital","startDate":"2021-07-02","conditions":"Breast Cancer, Adjuvant Therapy","enrollment":206},{"nctId":"NCT03329690","phase":"PHASE2","title":"DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2017-11-02","conditions":"Neoplasm, Gastrointestinal","enrollment":233},{"nctId":"NCT05030519","phase":"","title":"A Study of Diarrhea and Intestinal Flora Changes Caused by Pyrotinib in Breast Cancer","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2021-01-18","conditions":"Breast Cancer","enrollment":50},{"nctId":"NCT04757090","phase":"PHASE2","title":"89Zr-Trastuzumab PET/CT in Subjects With Previously Treated HER2-Positive Solid Tumors Scheduled to Receive Treatment With MT-5111","status":"WITHDRAWN","sponsor":"Washington University School of Medicine","startDate":"2021-12-31","conditions":"HER2-positive Solid Tumor, HER-2 Positive Cancer","enrollment":""},{"nctId":"NCT03319459","phase":"PHASE1","title":"FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Fate Therapeutics","startDate":"2018-01-18","conditions":"HER2 Positive Gastric Cancer, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma","enrollment":44},{"nctId":"NCT03521245","phase":"","title":"Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer","status":"UNKNOWN","sponsor":"OmicsWay Corp.","startDate":"2017-10-01","conditions":"HER2-positive Breast Cancer","enrollment":40},{"nctId":"NCT02855775","phase":"NA","title":"Monoclonal Antibodies Elimination in Breast Cancer Patient","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2013-09-25","conditions":"Breast Cancer","enrollment":76},{"nctId":"NCT04831528","phase":"","title":"Decision-making of ctDNA in Patients With mCRC After Failure of First-line Treatment Containing Cetuximab - a Single-center, Phase II Clinical Study","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2021-04-10","conditions":"Metastatic Colorectal Cancer","enrollment":100},{"nctId":"NCT01570036","phase":"PHASE2","title":"Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax","status":"COMPLETED","sponsor":"George E. Peoples","startDate":"2013-05-21","conditions":"Breast Cancer","enrollment":275},{"nctId":"NCT03912441","phase":"PHASE1","title":"First-In-Human Study to Evaluate Safety And Pharmacokinetics of Single Escalating Doses of BCD-147 (Bispecific Anti-HER2/HER2 Antibody) in Healthy Subjects","status":"COMPLETED","sponsor":"Biocad","startDate":"2019-01-30","conditions":"Healthy","enrollment":15},{"nctId":"NCT01104935","phase":"PHASE3","title":"National Surgical Adjuvant Study of Breast Cancer(N-SAS BC) 07 [RESPECT]","status":"COMPLETED","sponsor":"Comprehensive Support Project for Oncology Research","startDate":"2009-10-28","conditions":"Breast Cancer","enrollment":275},{"nctId":"NCT00238290","phase":"PHASE2","title":"Trastuzumab and Letrozole in Treating Postmenopausal Women With Progressive Advanced Breast Cancer","status":"COMPLETED","sponsor":"Swiss Cancer Institute","startDate":"2005-05","conditions":"Breast Cancer","enrollment":13},{"nctId":"NCT00300781","phase":"PHASE2","title":"Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer","status":"COMPLETED","sponsor":"Puma Biotechnology, Inc.","startDate":"2006-08-04","conditions":"Breast Neoplasms, Neoplasms","enrollment":136},{"nctId":"NCT00790816","phase":"PHASE1","title":"Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-10","conditions":"Neoplasms, Breast","enrollment":500},{"nctId":"NCT01304797","phase":"PHASE1","title":"Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Merrimack Pharmaceuticals","startDate":"2011-03","conditions":"Breast Cancer","enrollment":75},{"nctId":"NCT00811993","phase":"PHASE1","title":"A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2009-02","conditions":"Neoplasms","enrollment":104},{"nctId":"NCT01674062","phase":"PHASE2","title":"A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) in Participants With Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-05","conditions":"Breast Cancer","enrollment":95},{"nctId":"NCT02805829","phase":"PHASE1, PHASE2","title":"Combination Trastuzumab With Expanded Natural Killer Cells for Treating HER2-positive Gastric Cancer","status":"UNKNOWN","sponsor":"Xuzhou Medical University","startDate":"2017-01","conditions":"Gastric Cancer","enrollment":20},{"nctId":"NCT02030561","phase":"PHASE1, PHASE2","title":"NK Cell Infusions With Trastuzumab for Patients With HER2+ Breast and Gastric Cancer","status":"UNKNOWN","sponsor":"National University Hospital, Singapore","startDate":"2014-01","conditions":"Breast Cancer, Gastric Cancer","enrollment":29},{"nctId":"NCT00320385","phase":"PHASE3","title":"Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-11","conditions":"Neoplasms, Breast","enrollment":296},{"nctId":"NCT01441596","phase":"PHASE2","title":"Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-10","conditions":"Breast Neoplasms, Neoplasm Metastasis","enrollment":121},{"nctId":"NCT02013765","phase":"PHASE2","title":"A Study of Herceptin (Trastuzumab) Monotherapy in Patients With Metastatic Urothelial Cancer","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2001-01","conditions":"Urinary Tract Cancer","enrollment":5},{"nctId":"NCT00475670","phase":"PHASE2","title":"A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-10","conditions":"Breast Cancer","enrollment":44},{"nctId":"NCT01363986","phase":"PHASE2","title":"A Study of Herceptin (Trastuzumab) in Combination With Whole Brain Radiotherapy in Patients With HER-2 Positive Breast Cancer","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2011-09","conditions":"Breast Cancer","enrollment":3},{"nctId":"NCT02005484","phase":"PHASE2","title":"A Study of Herceptin (Trastuzumab) in Patients With Metastatic or Advanced Gastric Cancer With Disease Progression","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2004-01","conditions":"Gastric Cancer","enrollment":6},{"nctId":"NCT00412412","phase":"PHASE1","title":"CNF2024 (BIIB021) HER2- (QD) HER2+ (BIW w/Herceptin) PK/PD Study","status":"COMPLETED","sponsor":"Biogen","startDate":"2007-12","conditions":"Breast Cancer","enrollment":34}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":129,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Herceptin"],"phase":"phase_3","status":"active","brandName":"trastuzumab monotherapy","genericName":"trastuzumab monotherapy","companyName":"Comprehensive Support Project for Oncology Research","companyId":"comprehensive-support-project-for-oncology-research","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Trastuzumab targets and binds to the HER2/neu receptor on cancer cells, triggering an immune response and inhibiting cell growth. Used for Adjuvant treatment of HER2-positive breast cancer, Treatment of HER2-positive metastatic breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}